Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Develop...
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: GlobeNewswire
Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up Corrected M-AAT Comprised 94% of Total AAT with a Concomitant 84% Reduction in Mutant Z-AAT Following BEAM-302 60 mg Treatment Post-treatment Inducibility of AAT Observed During Respiratory Infection with a Patient Reaching ~30 µM Total AAT, Retaining 95% M-AAT Composition Well-tolerated Safety Profile Observed with Single Doses of BEAM-302 up to 75 mg; Safety Consistent Across Single-dose Part A and Part B Cohorts 60 mg Selected as Optimal Biological Dose, Supported by Strong Safety and Efficacy Profile Across Single-dose Cohorts; Global Pivotal Cohort Expected to Initiate in Second Half of 2026 Beam to Host Investor Webcast Today, March 25, 2026, at 8:00 a.m. ET CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- RBC Capital Maintains a Sector Perform Rating on Beam Therapeutics (BEAM), Here's Why [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics (BEAM) had its price target raised by Royal Bank Of Canada from $22.00 to $26.00. They now have a "sector perform" rating on the stock.MarketBeat
- Beam Therapeutics (BEAM) had its price target raised by Wedbush from $57.00 to $65.00. They now have an "outperform" rating on the stock.MarketBeat
- Beam Therapeutics Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
BEAM
Earnings
- 2/24/26 - Beat
BEAM
Sec Filings
- 3/5/26 - Form 8-K
- 2/26/26 - Form 4
- 2/24/26 - Form 144
- BEAM's page on the SEC website